Skip to content
Screener

Alnylam Pharmaceuticals ALNY Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$16.08M+30.7%

Other financials

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
Net income$164.5M+348%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation

See full
Market cap$29.33B-49.0%
Enterprise value$27.88B-50.8%
P/E40×
P/S6.1×-17.3×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 8:11 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001178670-26-000062
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Deferred revenue(831)(40,400)
Net cash provided by operating activities397,2289,495
Cash flows from investing activities:
Purchases of property, plant and equipment(56,513)(23,263)
Purchases of marketable securities(837,297)(861,199)
Sales and maturities of marketable securities485,986856,850
Proceeds from maturity of restricted and other investments66,72558,075
Purchases of restricted and other investments(22,000)(58,075)

Cover / Front Matter

FAQ

What is Alnylam Pharmaceuticals's payments to acquire property, plant, and equipment?
Alnylam Pharmaceuticals (ALNY) reported payments to acquire property, plant, and equipment of $34.68M in Q2 2026.
How has Alnylam Pharmaceuticals's payments to acquire property, plant, and equipment changed year-over-year?
Alnylam Pharmaceuticals's payments to acquire property, plant, and equipment increased by 142.6% year-over-year, from $14.29M to $34.68M.
What is the long-term trend for Alnylam Pharmaceuticals's payments to acquire property, plant, and equipment?
Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's payments to acquire property, plant, and equipment has grown at a -6.4% compound annual growth rate (CAGR), from $76.37M to $58.7M.

Ask your AI about Alnylam Pharmaceuticals's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude